UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
—————————
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
—————————
For the month of February 2007
Commission File Number: 001-31368
SANOFI-AVENTIS
(Translation of registrant’s name into English)
174, avenue de France, 75013 Paris, FRANCE
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. |
| Form 20-F x | Form 40-F o |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____ |
| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____ |
| Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. |
| Yes o | No x |
| If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________ |
|
|
|
|
In January and February 2007, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.
Exhibit List
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press release dated January 19, 2007 “S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone” |
|
Exhibit 99.2 |
Press release dated January 25, 2007 “FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine” |
|
Exhibit 99.3 |
Press release dated February 6, 2007 “Positive Recommendation for Acomplia® from the Transparency Committee in France” |
|
Exhibit 99.4 |
Press release dated February 6, 2007 “FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack”. |
|
|
2 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Dated: February 8, 2006 |
SANOFI-AVENTIS |
|
|
By: |
/s/ Patricia Kodyra |
|
|
Name: |
Patricia Kodyra |
|
|
Title: |
Associate Vice President |
|
|
3 |
|
Exhibit Index
|
Exhibit No. |
Description |
|
Exhibit 99.1 |
Press release dated January 19, 2007 “S-1 oral anticancer agent improves patients’ survival in adjuvant gastric cancer trial versus surgery alone” |
|
Exhibit 99.2 |
Press release dated January 25, 2007 “FDA Advisory Committee Recommends Licensure of New Pediatric Combination Vaccine” |
|
Exhibit 99.3 |
Press release dated February 6, 2007 “Positive Recommendation for Acomplia® from the Transparency Committee in France” |
|
Exhibit 99.4 |
Press release dated February 6, 2007 “FDA Grants Priority Review to Lovenox® (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for additional type of heart attack”. |
|
|
4 |
|